Rgia A Othman1, Semone B Myrie2, David Mymin3, Jean-Baptiste Roullet4, Robert D Steiner5, Peter J H Jones1. 1. Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Richardson Center for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada. 2. Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; Richardson Center for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: myrie@cc.umanitoba.ca. 3. Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 4. College of Pharmacy, Washington State University, Spokane, WA, United States; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, United States. 5. University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Abstract
BACKGROUND AND AIMS: Sitosterolemia displays high plasma total sterols [high plant sterols (PS) + normal to high total cholesterol (TC)] with normal to moderately elevated low-density lipoprotein (LDL) levels. High LDL, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL) particles, low high-density lipoprotein (HDL), and increased non-HDL and the ratios of TC and triglycerides (TG) to HDL can increase the risk for atherosclerosis. Ezetimibe (EZE) can reduce plasma PS and TC levels in sitosterolemia, but its effect on lipoprotein subclasses has not been previously reported. METHODS: Sitosterolemia patients (n = 8) were taken off EZE for 14 weeks (OFF EZE) and placed on EZE (10 mg/d) for 14 weeks (ON EZE). Serum lipids were measured enzymatically and lipoprotein subclasses were assessed by polyacrylamide gel electrophoresis. RESULTS: EZE reduced (p < 0.05) total sterols (-12.5 ± 4.1%) and LDL-sterol (-22.7 ± 5.7%) and its sterol mass of large VLDL (-24.4 ± 4.5%), VLDL remnants (-21.1 ± 7.9%) and large IDL (-22.4 ± 7.2%) compared to OFF EZE. EZE did not affect large LDL subclasses or mean LDL particle size (273.8 ± 0.6 vs. 274.6 ± 0.3 Å). EZE increased HDL-sterol (25.5 ± 8.0%, p = 0.008) including intermediate (34 ± 14%, p = 0.02) and large (33 ± 16%, p = 0.06) HDL. EZE reduced non-HDL-sterol (-21.8± 5.0%), total sterols/HDL (-28.2 ± 5.5%) and TG/HDL (-27.4 ± 6.5%, all p < 0.01). CONCLUSIONS: EZE improves VLDL and HDL subfraction distribution, thereby reducing the atherogenic lipid profile, thus providing potential clinical benefit in sitosterolemia beyond TC and PS reduction.
BACKGROUND AND AIMS: Sitosterolemia displays high plasma total sterols [high plant sterols (PS) + normal to high total cholesterol (TC)] with normal to moderately elevated low-density lipoprotein (LDL) levels. High LDL, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL) particles, low high-density lipoprotein (HDL), and increased non-HDL and the ratios of TC and triglycerides (TG) to HDL can increase the risk for atherosclerosis. Ezetimibe (EZE) can reduce plasma PS and TC levels in sitosterolemia, but its effect on lipoprotein subclasses has not been previously reported. METHODS:Sitosterolemiapatients (n = 8) were taken off EZE for 14 weeks (OFF EZE) and placed on EZE (10 mg/d) for 14 weeks (ON EZE). Serum lipids were measured enzymatically and lipoprotein subclasses were assessed by polyacrylamide gel electrophoresis. RESULTS: EZE reduced (p < 0.05) total sterols (-12.5 ± 4.1%) and LDL-sterol (-22.7 ± 5.7%) and its sterol mass of large VLDL (-24.4 ± 4.5%), VLDL remnants (-21.1 ± 7.9%) and large IDL (-22.4 ± 7.2%) compared to OFF EZE. EZE did not affect large LDL subclasses or mean LDL particle size (273.8 ± 0.6 vs. 274.6 ± 0.3 Å). EZE increased HDL-sterol (25.5 ± 8.0%, p = 0.008) including intermediate (34 ± 14%, p = 0.02) and large (33 ± 16%, p = 0.06) HDL. EZE reduced non-HDL-sterol (-21.8± 5.0%), total sterols/HDL (-28.2 ± 5.5%) and TG/HDL (-27.4 ± 6.5%, all p < 0.01). CONCLUSIONS: EZE improves VLDL and HDL subfraction distribution, thereby reducing the atherogenic lipid profile, thus providing potential clinical benefit in sitosterolemia beyond TC and PS reduction.
Authors: D P Mikhailidis; A S Wierzbicki; S S Daskalopoulou; N Al-Saady; H Griffiths; G Hamilton; D Monkman; V Patel; J Pittard; M Schachter Journal: Curr Med Res Opin Date: 2005-06 Impact factor: 2.580
Authors: Diane L Tribble; Michel Farnier; Geraldine Macdonell; Inna Perevozskaya; Michael J Davies; Barry Gumbiner; Thomas A Musliner Journal: Metabolism Date: 2008-06 Impact factor: 8.694
Authors: E S Nakou; T D Filippatos; M Georgoula; D N Kiortsis; A D Tselepis; D P Mikhailidis; M S Elisaf Journal: Curr Med Res Opin Date: 2008-05-29 Impact factor: 2.580
Authors: D S Freedman; J D Otvos; E J Jeyarajah; J J Barboriak; A J Anderson; J A Walker Journal: Arterioscler Thromb Vasc Biol Date: 1998-07 Impact factor: 8.311
Authors: Protasio Lemos da Luz; Desiderio Favarato; Jose Rocha Faria-Neto; Pedro Lemos; Antonio Carlos Palandri Chagas Journal: Clinics (Sao Paulo) Date: 2008-08 Impact factor: 2.365
Authors: Leticia C S Pinto; Ana P Q Mello; Maria C O Izar; Nagila R T Damasceno; Antonio M F Neto; Carolina N França; Adriano Caixeta; Henrique T Bianco; Rui M S Póvoa; Flavio T Moreira; Amanda S F Bacchin; Francisco A Fonseca Journal: Lipids Health Dis Date: 2021-09-29 Impact factor: 3.876